AbbVie wins FDA approval for new migraine indication Published: Apr 19, 2023 By Tristan Manalac BioSpace The FDA has approved an expanded indication for AbbVie’s Qulipta (atogepant) to treat patients […]
https://www.pharmalive.com/wp-content/uploads/2023/04/BioSpaceAbbVie4-19-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-04-19 12:47:152023-04-19 20:02:29AbbVie wins FDA approval for new migraine indication
